Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vocimagene amiretrorepvec-flucytosine gene therapy - Tocagen

Drug Profile

Vocimagene amiretrorepvec-flucytosine gene therapy - Tocagen

Alternative Names: Flucytosine prodrug activating therapy - Tocagen; Toca 511 & Toca FC; Toca 511 + 5-FC; Toca-511 + Toca-FC; Vocimagene amiretrorepvec + 5-fluorocytosine; Vocimagene amiretrorepvec + flucytosine

Latest Information Update: 05 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tocagen
  • Class Antineoplastics; Cytosine deaminase flucytosine gene therapies; Immunotherapies; Pyrimidinones; Small molecules
  • Mechanism of Action Antimetabolites; DNA synthesis inhibitors; Gene transference; Prodrug activators; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II/III Anaplastic astrocytoma
  • Phase I Glioma; Solid tumours
  • Preclinical Breast cancer

Most Recent Events

  • 29 Nov 2018 Tocagen and NRG Oncology (a member of the National Cancer Institute's National Clinical Trial Network) plan the phase II/III NRG-BN006 trial in Glioma (Newly diagnosed) in USA in 2019
  • 30 Sep 2018 Efficacy and adverse events from the phase Ib Toca 6 trial in Solid tumours presented at the International Cancer Immunotherapy Conference
  • 25 Sep 2018 Tocagen completes enrolment in the Toca 5 phase III trial for Glioblastoma in USA, Canada, Israel and South Korea (NCT02414165)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top